Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 2145.

https://doi.org/10.1182/blood-2019-131253

Published: 2019

Journal Articles

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

Pedro G Vianna, BSc,MD, Richard D. Press, MD PhD, Henning Stehr, PhD, Fei Yang, MD, Linda Gojenola, James L Zehnder, Jason Gotlib, MD MS

Blood (2019) 134 (Supplement_1): 1408.

https://doi.org/10.1182/blood-2019-124445

Published: 2019

Journal Articles

DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia

Brian Giacopelli, BS, Min Wang, Ada C Cleary, Yue-zhong Wu, MSc, Anna Reister Schultz, James S. Blachly, MD, Ann-Kathrin Eisfeld, MD, Kevin R Coombes, Clara D. Bloomfield, MD, Brian J. Druker, Jeffrey W. Tyner, John C. Byrd, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 1413.

https://doi.org/10.1182/blood-2019-126212

Published: 2019

Journal Articles

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 373.

https://doi.org/10.1182/blood-2019-131925

Published: 2019

Journal Articles

Heavy Menstrual Bleeding Under-Recognized in Menstruating Women Treated with Oral Anticoagulants

Vivia Chi, MDcal Student, Maureen Baldwin, MD, Bethany T. Samuelson Bannow, MD

Blood (2019) 134 (Supplement_1): 60.

https://doi.org/10.1182/blood-2019-131026

Published: 2019

Journal Articles

Patient and Family Engagement during Treatment Change to Emicizumab at a Hemophilia Treatment Center

Susan U Lattimore, Madolyn T Hofstetter, BS

Blood (2019) 134 (Supplement_1): 5796.

https://doi.org/10.1182/blood-2019-131030

Published: 2019

Journal Articles

Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2

Blood (2018) 132 (Supplement 1): 4053.

https://doi.org/10.1182/blood-2018-99-116199

Published: 2018

Journal Articles

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Bill H. Chang, MD PhD, Jessica Leonard, MD, Joelle Wolf, Michelle Degnin, BS, Kyle Lenz, MD, Beth Wilmot, PhD, Charles G. Mullighan, MBBS, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2018-99-115706

Published: 2018

Journal Articles

Clonal Hematopoiesis in Older Women with Extremely Skewed, Non-Random X-Inactivation Is Associated with Previous Cardiovascular and Cerebrovascular Events

Emily Marre, MPH, Julia Erin Wiedmeier, MD MPH, Zhenzhen Zhang, PhD, Hyunjung Lee, Dana Parker, Kelsey Westerlund, Christopher A. Eide, Catherine Kato, Maros Ferencik, MD PhD, Brian J. Druker, MD, Kim-Hien Dao, DO, PhD

Blood (2018) 132 (Supplement 1): 2574.

https://doi.org/10.1182/blood-2018-99-120323

Published: 2018

Journal Articles

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

Lauren K. Brady, PhD, David Soong, PhD, Evan F. Lind, PhD, Yoko Kosaka, PhD, Adam J. Lamble, MD, Michael Schaffer, PhD, Brendan P. Hodkinson, PhD, Clare Lefave, PhD, Ted Laderas, PhD, Shannon K. McWeeney, PhD, Homer Adams, III, PhD, Yann Abraham, PhD, Pegah Safabakhsh, MS, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Fei Huang, PhD

Blood (2018) 132 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2018-99-118424

Published: 2018

Journal Articles

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Brian S. White, PhD, Suleiman A. Khan, PhD, Muhammad Ammad-ud-din, PhD, Swapnil Potdar, MSc, Mike J Mason, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD, Caroline A Heckman, PhD, Olli Kallioniemi, MD PhD, Stephen E Kurtz, PhD, Kimmo Porkka, MD PhD, Jeffrey W. Tyner, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Justin Guinney, PhD

Blood (2018) 132 (Supplement 1): 2763.

https://doi.org/10.1182/blood-2018-99-111916

Published: 2018

Journal Articles

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Stephen E Kurtz, PhD, Christopher A. Eide, Narain P. Dubey, Andy Kaempf, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Anupriya Agarwal, PhD

Blood (2018) 132 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2018-99-117537

Published: 2018

Journal Articles

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Jessica Leonard, MD, Yoko Kosaka, PhD, Pavani Malla, MS, Brandon Hayes-Lattin, MD, Adam J. Lamble, MD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Bill H. Chang, MD PhD, Evan F. Lind, PhD

Blood (2018) 132 (Supplement 1): 2694.

https://doi.org/10.1182/blood-2018-99-119301

Published: 2018

Journal Articles

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Anna Reister Schultz, BS, Thomas Jacob, Christopher A. Eide, Samantha L Savage, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Tania Q. Vu, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2018-99-115387

Published: 2018

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

Journal Articles

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Blood (2018) 132 (Supplement 1): 559.

https://doi.org/10.1182/blood-2018-99-118494

Published: 2018

Journal Articles

Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, Cristina E. Tognon, PhD, Motomi Mori, PhD, Max J. Gordon, MD, Jeffrey W. Tyner, PhD, Alexey V Danilov, MD PhD, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 214.

https://doi.org/10.1182/blood-2018-99-117468

Published: 2018

Journal Articles

Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia

Theodore Braun, MD PhD, Amy Foley, MEng., Brian J. Druker, MD, Julia E. Maxson

Blood (2018) 132 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2018-99-119213

Published: 2018

Journal Articles

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Kim-Hien Dao, DO,PhD, Robert H. Collins, MD, Jorge E. Cortes, MD, Michael W. Deininger, MD PhD, Brian J. Druker, MD, Jason R. Gotlib, MDMS, Tara Alyson Macey, PhD, Stephen T Oh, MD PhD, Jeffrey W. Tyner, PhD, Elliott F. Winton, MD

Blood (2018) 132 (Supplement 1): 350.

https://doi.org/10.1182/blood-2018-99-119476

Published: 2018

Journal Articles

Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial

Eytan M. Stein, MD, Abigail Shoben, Uma Borate, MD, Maria R. Baer, MD, Wendy Stock, MD, Prapti A. Patel, MD, Tibor Kovacsovics, MD, William Blum, MD, Jo-Anne Vergilio, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, Sonja Marcus, MPH, Mona Stefanos, MBChB, Jordan Chervin, Brian J. Druker, MD, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 287.

https://doi.org/10.1182/blood-2018-99-118287

Published: 2018

NARROW

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

Heavy Menstrual Bleeding Under-Recognized in Menstruating Women Treated with Oral Anticoagulants

Patient and Family Engagement during Treatment Change to Emicizumab at a Hemophilia Treatment Center

Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Clonal Hematopoiesis in Older Women with Extremely Skewed, Non-Random X-Inactivation Is Associated with Previous Cardiovascular and Cerebrovascular Events

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only